Phaseline

Targets › NA

NA: drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on NA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Capital Medical UniversitySuraxavir marboxil
Neuraminidase inhibitor
NAPhase 3InfluenzaMar 2027
University Medical Centre Ljubljanaoseltamivir
Neuraminidase inhibitor
NAPhase 3InfluenzaMar 2028
George Washington UniversityZanamivir
Neuraminidase inhibitor
NAPhase 2Dengue FeverAug 2027

Conditions

Influenza (2) Dengue Fever (1)

Modalities

small molecule (3)

Companies

Capital Medical University (1) George Washington University (1) University Medical Centre Ljubljana (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.